After one of the more turbulent regulatory sagas in recent memory, the Food and Drug Administration has cleared Replimune's RP1, given in combination with the immunotherapy nivolumab, for patients with advanced melanoma that has progressed after anti-PD-1 treatment. It is a major win for the biotech, whose stock had been battered by the ordeal, and, more importantly, a new option for a group of patients who had very few. But the win is a conditional one. The clearance came as an accelerated approval, tied to an ongoing Phase 3 confirmatory trial whose results are years away, and it defers rather than resolves the scientific question that sat at the center of the entire fight.
The path here was genuinely rocky. The FDA rejected the drug twice before an advisory committee voted 10 to 3 in late July that the evidence was clinically meaningful, clearing the way for this approval. Understanding why the agency balked twice, and what its eventual yes does and does not settle, matters more than the headline that a long-delayed drug finally got through.
The FDA's objection was real, not obstruction
It would be easy to read two rejections as bureaucratic foot-dragging in the face of a promising therapy, but the agency's core concern was scientifically legitimate. RP1, an oncolytic virus injected directly into tumors, was tested in combination with nivolumab, an already-approved immunotherapy, in a single-arm trial with no control group. That design makes it impossible to isolate how much of the benefit came from RP1 and how much from the nivolumab patients were also receiving. This is the classic "contribution of components" problem: when a new drug is approved on the strength of a combination study with no comparison arm, you cannot be sure the new drug is actually adding anything.
The agency's worry had a sharper edge, too. In the trial, a large share of responding patients had all of their tumors injected with RP1, and roughly half lacked measurable non-injected lesions, which raised a pointed question about whether RP1 works systemically, throughout the body, as metastatic melanoma requires, or mainly locally, shrinking the specific tumors into which it is injected. Local activity is far less valuable against a cancer that has spread. The FDA raised no safety concerns at any point; the entire dispute was about whether the evidence could show that RP1 itself, and not its well-established partner drug, was driving a durable, body-wide benefit.
The unmet need, and a striking durability signal
Weighing against that uncertainty was a genuinely serious counterweight. Patients whose melanoma has progressed after anti-PD-1 therapy have few good options; the main approved alternative, TIL therapy, is complex, toxic, and not widely available, a limitation the advisory committee returned to repeatedly in its discussion. Into that gap came data that, single-arm caveats notwithstanding, were hard to dismiss.
The IGNYTE trial reported an objective response rate around a third, but the more arresting numbers were about durability. The median duration of response ran to roughly 33 months, and three-year overall survival reached 47.8% across all treated patients and 83.5% among those who responded. For a refractory-melanoma population with historically limited options, long-term survival at those levels is a striking signal of meaningful benefit. That is why the advisory panel, by a 10-to-3 margin, judged the results evaluable and clinically meaningful even as the design questions remained unresolved. The signal was strong; the attribution was not clean; and those two facts pulled in opposite directions.
Accelerated approval is built for exactly this tension
The predicament RP1 posed, a compelling but imperfectly attributable benefit for patients who cannot afford to wait, is the precise situation accelerated approval was designed to handle. The mechanism exists to resolve the standing trade-off between the certainty of the evidence and the speed of access, by allowing the FDA to approve a therapy on promising early data while requiring a confirmatory trial to verify the benefit, with the option to withdraw the drug if that trial fails.
RP1's path is a textbook, if unusually contentious, version of this bargain. The confirmatory study, IGNYTE-3, is a randomized, controlled trial comparing RP1 plus nivolumab against physician's choice of therapy, with overall survival as its primary endpoint, and it is already enrolling. Crucially, that design can do exactly what the single-arm IGNYTE trial could not: isolate RP1's contribution by comparing patients who receive it against patients who do not. The deal, in effect, is that patients get access now, on the strength of the early durability data, and the definitive answer arrives later, when IGNYTE-3 reports.
The approval defers the question rather than answering it
This is the essential point that the celebratory framing tends to obscure. The FDA's yes does not resolve the scientific dispute that produced two rejections. It postpones it. The question of whether RP1 genuinely and systemically contributes to the benefit, the very thing a single-arm trial could not establish, is precisely what the randomized IGNYTE-3 is built to determine. So the evidence the agency twice found insufficient is now the evidence the confirmatory trial must generate.
Read plainly, the approval is a bet, structured by accelerated approval's verify-later logic, that the durable survival seen in IGNYTE is real and attributable to RP1 rather than to nivolumab alone or to local injection effects. It is a defensible bet, given the strength of the durability data and the depth of the unmet need, and it is one that patients benefit from immediately. But it remains a bet, and its resolution lies not in this decision but in a trial that will not deliver its verdict until the end of the decade. The drug is available; the proof is pending.
The process, separately, was unusually erratic
One more feature of this saga deserves attention, because it is a problem distinct from the merits of the final decision. What set the RP1 story apart was not the accelerated-approval tension, which is common, but the FDA's own inconsistency along the way. The company said the second rejection contradicted positions the agency itself had taken at a formal meeting months earlier, and the review was marked by leadership disagreements, turnover on the review team, and limited interaction with the sponsor. This was not simply a cautious agency holding a firm line against an eager company; it was an agency that appeared, at least from the outside, to move its own goalposts and to struggle internally before arriving at yes.
That erraticism carries real costs regardless of whether the final call was correct. Drug developers depend on consistent, predictable guidance to design their trials and commit enormous sums, and patients depend on it to get therapies without needless delay. An agency that signals one standard and then applies another, amid turnover and internal disagreement, destroys time, capital, and, most consequentially, months that refractory patients do not have. Crediting the FDA's legitimate scientific concerns and criticizing the unpredictability of its process are not in tension; both can be true, and here both appear to be.
For the patients this drug is meant to help, the meaning of the day is real and worth stating without hedging: a group that had almost nothing now has a new option with a genuine chance of durable benefit, and the survival figures behind it offer hope that is not false. For the science, the approval settles nothing; it relocates the unanswered question, whether RP1 itself drives the benefit, from the review division to a confirmatory trial where a randomized design can finally answer what a single arm never could. And the jagged path it took there is a reminder that even an outcome good for patients can emerge from a process whose unpredictability exacts its own price. The true verdict on RP1 is not this clearance. It is IGNYTE-3, and it is still years away.
Primary sources
- STAT News, in reporting by Elaine Chen, for the FDA's clearance of RP1 for advanced melanoma after two prior rejections, the late-July advisory committee vote, and the dependence of full approval on the ongoing Phase 3 confirmatory trial.
- CancerNetwork and CURE for the July 30, 2026 Cellular, Tissue, and Gene Therapies Advisory Committee 10-3 vote that the IGNYTE results were evaluable and clinically meaningful, the nonbinding nature of that vote, the limitations of TIL therapy as the main approved alternative, and the confirmatory-trial timeline.
- OncLive, Targeted Oncology, and Dermatology Times for the regulatory history, including the July 2025 first complete response letter finding IGNYTE not adequate and well-controlled, the April 2026 second CRL citing the inability to isolate RP1's contribution in a single-arm trial and population heterogeneity, the observations that a large share of responders had all lesions injected and lacked measurable non-injected lesions, the reported efficacy figures, including an objective response rate roughly 33 to 34%, median duration of response near 33 months, and three-year overall survival of 47.8% overall and 83.5% among responders, the company's statement that the second CRL contradicted prior FDA positions, and the reports of FDA leadership disagreements and review-team turnover.
- Replimune's SEC filings and releases for the design of the confirmatory IGNYTE-3 trial, comparing RP1 plus nivolumab against physician's choice, with overall survival as the primary endpoint, roughly 400 patients, and actively enrolling.